Boehringer and SBP Group Sign $7B Cancer Drug Deal

Ingelheim, Germany, and Hong Kong, China, November 4, 2026

Six Preclinical Programs Target Next-Generation Cancer Therapies

The new agreement covers six biologic preclinical programs originating from two SBP Group subsidiaries. Five programs are associated with LaNova Medicines (Shanghai) Co., Ltd., a wholly owned subsidiary of SBP Group, while the remaining program originates from Beijing Tide Pharmaceutical Co., Ltd. These programs are designed to explore innovative approaches to cancer treatment using ADC and T-cell engager technologies. Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine monoclonal antibodies with potent therapeutic agents. The antibody component is designed to recognize specific markers expressed on cancer cells and deliver the attached drug payload more selectively to the target. This approach aims to improve targeted treatment delivery while potentially reducing exposure of healthy tissues to certain toxic agents. Meanwhile, T-cell engagers (TcEs) are engineered biologic molecules designed to bring immune T cells into close proximity with cancer cells. By connecting immune cells with tumor-associated targets, these therapies aim to activate the body’s immune response and promote the destruction of malignant cells. Both technologies represent important areas of innovation in oncology research, particularly for cancers that remain difficult to treat using conventional therapeutic approaches. The six programs remain at the preclinical development stage. Consequently, their safety and effectiveness in humans have not yet been established, and further research and clinical evaluation will be required before they can potentially become approved medicines.

US$358 Million Upfront and Potential US$7 Billion Milestones

Under the licensing and option agreement, SBP Group will receive US$358 million in upfront and near-term payments. In addition, the company is eligible for potential payments of up to US$7 billion based on the achievement of specified option-exercise, development, regulatory and commercial milestones. SBP Group may also receive tiered royalties, including rates reaching up to double-digit percentages, on potential future product sales. The agreement establishes a development structure in which SBP Group will undertake the early development activities for the six programs. Once agreed clinical milestones are achieved, Boehringer Ingelheim will have the option to obtain exclusive development, manufacturing and commercialization rights for the relevant candidates. For four programs, the potential licensing rights will cover territories outside mainland China, Hong Kong and Macau. For the remaining two programs, Boehringer Ingelheim may obtain worldwide rights. This structure provides the German pharmaceutical company with opportunities to expand its global oncology portfolio while allowing SBP Group to contribute its research capabilities and advance the programs during their early development stages. The partnership also represents the second oncology collaboration between the two companies, reflecting their continuing interest in combining complementary research and development capabilities.

Partnership Strengthens Global Oncology Research

For Boehringer Ingelheim, the agreement supports its strategy of building a differentiated oncology portfolio that includes cancer cell-directed therapies and immuno-oncology approaches. The company continues to invest in innovative therapeutic technologies designed to address significant unmet medical needs across different cancer types. The collaboration also reinforces Boehringer Ingelheim’s commitment to China’s pharmaceutical innovation ecosystem. Its China Research and Development Center in Shanghai is intended to strengthen early clinical development and external innovation activities while connecting research originating in China with its global development network. For SBP Group, the agreement represents an important step in its international expansion strategy. Through its subsidiaries LaNova Medicines and Beijing Tide, the company is contributing multiple early-stage biologic programs to a global pharmaceutical partnership. Combining its discovery platforms and early-development expertise with Boehringer Ingelheim’s international oncology capabilities could help advance these programs toward clinical evaluation. Overall, the partnership highlights the growing importance of international pharmaceutical collaborations in developing innovative cancer medicines. With six preclinical programs, substantial upfront payments and significant potential milestone opportunities, the agreement represents a major development in ADC research, T-cell engager technology and next-generation oncology drug development.

Source: Boehringer Ingelheim, Sino Biopharmaceutical press release